and Ankur morning, then Good will an today. I provide overview you updates everyone, will outlook. Dave. you, and for some Thank our provide company our and thank and joining position financial overall, us perspective regarding on
about enthusiastic we incredibly Team I'm First, created the opportunity have at Summit.
our all our is us Team something I of that is to at something and of that as accept and Our important very us to mission stakeholders. Summit all obligation
in in-license the a difference announced discovering pioneer color may Akeso our give company quality improving by U.S., founded with duration as about in XXXX the patients' leading to CEO. to she antibodies as stakeholder a scaling antibody, addition Crown, and innovative and and Chairwoman ivonescimab. intend all Akeso in this Akeso. development while to we academic who Biosciences. She the who is the experience leadership a developing December, By taking Akeso XX has by Dr. intending antibodies. At served to a at building the for company. and Pfizer. a in world-class in Michelle is to R&D, full bispecific partnership in including their leadership of overall currently China Xia, like Bayer, Genomics, return. Akeso's in to pharmaceutical and deep exceptional from innovative scientific and experience therapy, are with the Crown her based In venture create Celera lives company in a the through years is role significant has I'd and leadership led of the discovery, some is of where innovative and bispecific China, research in we potential make Dr. companies Xia her across experience U.K. and experience benefit joint ivonescimab, in U.S. manufacturing responsibility in also industry we
rich has in bispecific and inhibitor and X clinical antibody PD-X over novel trials. in a taken pipeline XX indications including XX for drug with pivotal for CTLA-X XX of candidates, trials called XX discovered oncology internally a various diversified has China: cadonilimab. drug Akeso antibody Akeso approved in has part a drugs PD-X candidates X company, including a As Akeso antibodies. development, drug bispecific stages over
and Ivonescimab, approaching also SMTXXX, a this and with is anti-PD-X single a tumor innovation has of molecule, a of approved which the in fight and Anti-VEGF assists an effectively. antibody of Cadonilimab that an deplete anti-angiogenesis is system the as Kong, any space. helps the immune the the to demonstrating new together X employees brings refer PD-X-based vessels publicly we is tumors. in -- in in Anti-PD-X in therapy market, system antibody billion. the Akeso's $X tumor more bispecific Hong effects the killing and over expertise effects bispecific X,XXX blood targets valuation first therapy anti-VEGF. Akeso combining listed allows major to immunotherapy along immune
the cell technology due is Ivonescimab advanced as these weight is lack intends locally individually. to for therapy block PD-X, that of trials monotherapy enhance China, pathways X Ivonescimab antitumor PD-X/VEGF stability of to low effectively PD-X expression combined anti-VEGF as agents bispecific In obstacles due heterogeneity more and treatment-naive is engineered has to and a have bispecific agent with ivonescimab. antibody or of patients to antibodies targets these the bispecific activity whose well the administering positive microenvironment lung VEGF combined underway Akeso's III X be the bispecific X taking to believed patients in compared way in of under for unique Phase have Akeso Both for cell PD-LX antibodies who and today, such ivonescimab after coexpression progressed with challenges, tyrosine of of are as trials metastatic the manufacturing EGFR and structural China. non-small expression inhibitor. cancer single the tumors lung antibodies. non-small high ivonescimab overcome cancer molecular a chemotherapy that most kinase view advanced first of antibodies, process and block tumor clinic bispecific create and development levels tetrabody In to to
in in have indications Akeso with in Additionally, indications ivonescimab China. is mentioned well has which progressed ivonescimab in chemotherapy, in combined Phase inhibitor which non-small just combination cell as platinum-based received with in in II breakthrough III as chemotherapy that trials trials engaged treatment currently patients for with PD-X follows: cancer X lung after who currently we China as therapy is Phase the X designations
substantive rights, We low on have licensed Akeso $XXX and billion Japan. million to of milestones agreed eligible to up net milestones to our regulatory double-digit receive SMTXXX the Canada, billion. to rights up royalties In commercialization sales Akeso, States, in the to we United upfront $X.XX will and these Akeso to SMTXXX. exchange for of receive $X.XX meaningful Europe pay with
Our development indications. of SMTXXX cell begin lung intent is to cancer and North America Europe non-small our in in
oncology other next appropriate communication to we significant to well and support upcoming and territory, foundation areas, to the the key upon with months pursue provide with we couple have expansion our of over late-stage as opinion non-small deal health to have with drug in term more trials scheduled steps, in basis. own different FDA we will that opportunity trials and including to preparing cancer. of specific the in and past needed be and expand as as consummated, timely on work licensed a territories, in build commercial readying color a expanding laid player a with trials we for by number in to been clinical our have we highly hiring feedback of obtain have the proposed clinical sites long our appropriately discuss next multiple evaluation to chain our channels sources and trials begun bispecific in meetings and the occasions of to Operationally, space. have upon lung intend whom clinical the from supply supply as approach cell scale-up our on We executing the we Akeso begin the leaders met FDA Based respect are supply network engaged with of multiple different late-stage multiple the from the indications clinical to to multiple we context in excellent FDA trial and vendors authorities clinical the our having year the over and on
provide will Finally, $XXX week. we our details million position to closed fully our offering Ankur financial additional subscribed last as rights shortly.
to of with oversubscribed the Team over proud level offering. Summit X,XXX bit the more details million target this of to Ankur position. a will give things participation turn With extremely in that our rights we that, accounts I'm acquiring Ankur? our offering The appreciates $XXX expression of I on financial was confidence. above had shares. over
